Moneycontrol PRO
HomeNewsBusinessEarningsLupin Q1 results: Net profit at Rs 453.33 crore from year-ago loss, tops Street estimates

Lupin Q1 results: Net profit at Rs 453.33 crore from year-ago loss, tops Street estimates

The Street had pegged Lupin’s net profit at Rs 276.2 crore for the April- June quarter

August 04, 2023 / 10:02 IST
Lupin Q1 earnings
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Pharma major Lupin Ltd. recorded a consolidated net profit of Rs 453.33 crore for the April-June quarter FY24, as against a consolidated net loss of Rs 86.8 crore reported in the same period a year ago.

    The drugmaker's net profit for the period topped analyst’s estimate of Rs 276.2 crore, pegged by a consensus of seven brokerages polled by Moneycontrol.

    The Mumbai-based drugmaker also reported a 28.6 percent increase in revenue at Rs 4,814.06 crore as against Rs 3,743.8 crore in the year-ago period.

    The Street had pegged revenue for the company at Rs 4,530.9 crore for the quarter under review.

    The company reported EBITDA of Rs 879.1 crore, compared to Rs 237.9 during the same period a year ago. EBITDA margins were 18.5 percent in the quarter, up 1190 basis points compared with the same period a year ago.

    "Our India branded business has bounced back to double-digit growth despite NLEM price reductions. With the clearance of Pithampur Unit-2 we expect to add to the product approvals for the US region," said Nilesh Gupta, Managing Director, Lupin Ltd.

    North America sales for the quarter were Rs. 1,590.5 crore, up 57.4 percent compared to Rs 1,010.4 crore in the same quarter previous year and accounted for 34 percent of Lupin’s global sales.

    India formulation sales for the quarter were Rs 1,638.4 crore, up 9.8 percent as compared to Rs 1,492 crore in the same quarter previous year. This accounted for 35 percent of Lupin’s global sales.

    Global API Sales for the quarter reported were Rs 337.1 crore, up 32.1 percent as compared to Rs 255.1 crore in Q1 FY2023; and accounted for 7 percent of Lupin’s global sales.

    Investment in R&D was Rs 367.9 crore (7.8 percent of sales) for the April-June quarter compared with Rs 305 crore (7.0 percent of sales) for Jan- Mar quarter. Lupin received approval for 4 ANDAs from the U.S. FDA in the quarter.

    Shares of the company closed at Rs 1,035.35 a piece on August 3, up 4.10 percent, ahead of the announcement of the quarterly earnings on NSE.

     

    Moneycontrol News
    first published: Aug 3, 2023 10:13 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347